Cholesterol Reduction Yields Clinical Benefit
| Autor: | J F Heyse, N C Santanello, J E Rossouw, C D Furberg, A L Gould |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Male
medicine.medical_specialty Statin medicine.drug_class Hypercholesterolemia Coronary Disease Cholesterol Dietary chemistry.chemical_compound Chd mortality Physiology (medical) Internal medicine Humans Medicine Clofibrate Dextrothyroxine biology business.industry Cholesterol Cholesterol lowering Estrogens Coronary heart disease Total mortality Endocrinology chemistry Meta-analysis HMG-CoA reductase biology.protein Cardiology Gemfibrozil Cardiology and Cardiovascular Medicine business |
| Zdroj: | Circulation. 91:2274-2282 |
| ISSN: | 1524-4539 0009-7322 |
| DOI: | 10.1161/01.cir.91.8.2274 |
| Popis: | Background There has been a continuing debate about the overall benefit of cholesterol lowering. We performed a novel meta-analysis of all randomized trials of more than 2 years’ duration (n=35 trials) to describe how coronary-heart-disease (CHD), non-CHD, and total mortality are related to cholesterol lowering and to type of intervention. Methods and Results The analytic approach was designed to separate the effects of cholesterol lowering itself from the other effects of the different types of intervention used. For every 10 percentage points of cholesterol lowering, CHD mortality was reduced by 13% ( P P P P P P P Conclusions The results suggest that cholesterol lowering itself is beneficial but that specific adverse effects of fibrates and hormones increase the risk of CHD (hormones only), non-CHD, and total mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|